Valuation: Intellipharmaceutics International Inc.

Market Cap 1.41M 1.22M 1.14M 1.04M 1.97M 134M 2M 13.41M 5.26M 66.84M 5.28M 5.17M 224M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.17M 2.95M 2.71M 5.12M 348M 5.2M 34.8M 13.66M 173M 13.7M 13.4M 581M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
3 years 0
Extreme 0
0.15
5 years 0
Extreme 0
0.3
10 years 0
Extreme 0
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-0.53%-3.95%+55.23%+152.74% 1,030B
+0.21%-2.68%+55.61%+53.02% 617B
-2.51%-3.25%+32.76%+67.76% 455B
+0.06%-0.42%+37.53%+30.67% 350B
-0.14%-0.24%+34.41%+39.01% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+2.43%+30.52%+64.49% 209B
-0.82%+0.70%+15.96%+71.01% 163B
Average -1.24%+1.24%+29.58%+50.11% 361.27B
Weighted average by Cap. -1.02%-0.11%+38.70%+72.68%

Financials

2021 2022
Net sales - 65.73K 57.14K 53.18K 48.83K 92.21K 6.27M 93.64K 627K 246K 3.12M 247K 241K 10.47M
Net income -5.15M -4.47M -4.16M -3.82M -7.22M -491M -7.33M -49.07M -19.26M -245M -19.32M -18.9M -820M -2.89M -2.51M -2.34M -2.15M -4.06M -276M -4.12M -27.59M -10.83M -137M -10.86M -10.62M -461M
Net Debt 1.15M 996K 927K 851K 1.61M 109M 1.63M 10.92M 4.29M 54.44M 4.3M 4.21M 183M 2.24M 1.95M 1.81M 1.67M 3.15M 214M 3.19M 21.39M 8.39M 107M 8.42M 8.24M 357M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock